No results found for “”
No results found for filter “”
-
Blog articles 11.12.24
The origins and privileges of self-regulation
Self-regulation plays a vital role in governing how pharmaceutical companies promote medicines, interact with health professionals and collaborate with...
Read Article -
Statements & press releases 10.12.24
Patients and society set to benefit from innovation which could “alleviate significant global disease...
The Pipeline review is an important reminder that many people continue to live with debilitating and life limiting disease, for whom new medicines could...
Read Article -
Blog articles 09.12.24
EFPIA response to ‘Guidance on outcomes for joint clinical assessments’
We remain optimistic that the flexibility included in the guideline is applied by the assessors in a pragmatic approach. Looking into the future, we hope...
Read Article -
Statements & press releases 05.12.24
9 ways to maximise the impact of the future EU Framework Programme for Research and Innovation (FP10) ...
Ahead of the discussions on the EU future Framework Programme for Research and Innovation (FP10), EFPIA is putting forward nine recommendations to help...
Read Article -
Statements & press releases 05.12.24
Pharmaceutical innovators are concerned over not enough advice meetings being offered in 2025 for discussing...
From 12 January 2025 the EU HTA Regulation will apply and the first JCAs will be performed to assess the relative clinical effectiveness of new innovative...
Read Article -
Blog articles 04.12.24
Resetting Europe’s Innovation Compass
Europe’s pharmaceutical sector has grown slowly for 25 years and its share of research is shrinking. It’s time to turn things around.
Read Article -
Statements & press releases 03.12.24
EFPIA response to EPSCO meeting
Today’s EPSCO meeting covered a number of health files. EFPIA particularly welcomes the adoption of council conclusions on cardiovascular health. With...
Read Article -
Statements & press releases 26.11.24
Urgent policy reforms needed to support the future of Europe’s biopharma SMEs, says EFPIA
SMEs are critical to the future of European life sciences and patients. We need policymakers to get behind an ambitious strategic vision for the competitiveness...
Read Article -
Blog articles 20.11.24
European Antibiotic Awareness Day: Urgent Need for Sustainable Antimicrobial R&D to Combat Superbugs
In Europe alone, antimicrobial resistance or AMR results in 35,000 deaths annually, with healthcare costs and productivity losses estimated at €1.5 billion...
Read Article -
EFPIA News 18.11.24
Breaking barriers in Rare Disease Research: The Rare Disease Moonshot at two years
Rare diseases impact millions globally, yet fewer than 5% of the over 7,000 identified have treatments, underscoring an urgent need for action. The Rare...
Read Article -
Blog articles 14.11.24
INNODIA: A Success Story in Type 1 Diabetes Research and Treatment (Guest blog)
Type 1 Diabetes (T1D) is an autoimmune disease where the body’s own immune system mistakenly attacks insulin-producing beta cells in the pancreas. It’s...
Read Article -
Statements & press releases 13.11.24
Despite a decade of gradual growth, R&D spending in Europe outpaced by the US – with increasing competition...
Boosting European competitiveness to kickstart growth requires concerted, collective action; urgent implementation of a coherent life sciences strategy...
Read Article
No results found for “”
No results found for filter “”
-
EFPIA News 18.11.24
Breaking barriers in Rare Disease Research: The Rare Disease Moonshot at two years
Rare diseases impact millions globally, yet fewer than 5% of the over 7,000 identified have treatments, underscoring an urgent need for action. The Rare...
Read Article -
EFPIA News 26.09.24
EFPIA position on opt-out in the EHDS Regulation
EFPIA stresses the importance of avoiding fragmentation and bias, clarifying the scope of the opt-out by limiting it to personal data and creating a centralised...
Read Article -
EFPIA News 11.07.24
NIRO: Navigating innovation and research opportunities
A new tool to help navigate the complex world of health R&I funding programmes.
Read Article -
EFPIA News 08.07.24
Breaking down barriers: Making cross-border access to clinical trials a reality
Collaborative effort by EFGCP and EFPIA develops action plan to address participation barriers in Europe
Read Article -
EFPIA News 12.06.24
New data from EFPIA reveals multiple factors leading to unequal access to medicines for patients across...
"Whatever the reason, whatever the cause, we stand ready to play our part in reducing the time it takes for patients to access the medicines we discover,...
Read Article -
EFPIA News 04.06.24
Insights from EFPIA's Reliance Webinar
On the 19th of March EFPIA have hosted a joint industry webinar on Reliance, providing a platform for information and discussion on use of EMA assessment...
Read Article -
EFPIA News 26.04.24
Journal article - Evolving assessment pathways for precision oncology medicines to improve patient access:...
This study describes challenges in assessing PO and TA medicines, explores possible solutions, and provides actionable recommendations to facilitate an...
Read Article -
EFPIA News 26.04.24
White paper on circular economy
Continued adoption of circular economy principles into the pharmaceutical sector can reduce materials extraction and operational waste, contribute to a...
Read Article -
EFPIA News 28.03.24
NIRO: Navigating Innovation & Research Opportunities
NIRO helps you find available European and international funds for research & innovation.
Read Article -
EFPIA News 13.02.24
European business calls for deepening the EU Single Market and renewing the dynamic of European integration...
Read the joint statement from 26 trade associations.
Read Article -
EFPIA News 06.02.24
Recording Now Available: EJP RD-EFPIA Joint Advanced Webinar on Real-World Data, Machine Learning, and...
...
Read Article -
EFPIA News 27.10.23
Stefan Oelrich's interview at the POLITICO Health Care Summit
Watch the recording.
Read Article
No results found for “”
No results found for filter “”
-
Statements & press releases 10.12.24
Patients and society set to benefit from innovation which could “alleviate significant global disease...
The Pipeline review is an important reminder that many people continue to live with debilitating and life limiting disease, for whom new medicines could...
Read Article -
Statements & press releases 05.12.24
9 ways to maximise the impact of the future EU Framework Programme for Research and Innovation (FP10) ...
Ahead of the discussions on the EU future Framework Programme for Research and Innovation (FP10), EFPIA is putting forward nine recommendations to help...
Read Article -
Statements & press releases 05.12.24
Pharmaceutical innovators are concerned over not enough advice meetings being offered in 2025 for discussing...
From 12 January 2025 the EU HTA Regulation will apply and the first JCAs will be performed to assess the relative clinical effectiveness of new innovative...
Read Article -
Statements & press releases 03.12.24
EFPIA response to EPSCO meeting
Today’s EPSCO meeting covered a number of health files. EFPIA particularly welcomes the adoption of council conclusions on cardiovascular health. With...
Read Article -
Statements & press releases 26.11.24
Urgent policy reforms needed to support the future of Europe’s biopharma SMEs, says EFPIA
SMEs are critical to the future of European life sciences and patients. We need policymakers to get behind an ambitious strategic vision for the competitiveness...
Read Article -
Statements & press releases 13.11.24
Despite a decade of gradual growth, R&D spending in Europe outpaced by the US – with increasing competition...
Boosting European competitiveness to kickstart growth requires concerted, collective action; urgent implementation of a coherent life sciences strategy...
Read Article -
Statements & press releases 05.11.24
Joint statement from the human pharmaceutical industry on the Urban Wastewater Treatment Directive (UWWTD)...
EFPIA and AESGP, representing the human pharmaceutical industry in Europe, acknowledge, with some reservations, the approval by the Council of the European...
Read Article -
Statements & press releases 22.10.24
60,000 fewer clinical trial places for Europeans, despite global surge in research projects.
"For Europe to be competitive, it needs to function as a unified region" says Nathalie Moll.
Read Article -
Statements & press releases 18.10.24
EFPIA position on the Urban Wastewater Treatment Directive
EFPIA, its member companies and national associations are concerned by the impact that the Urban Wastewater Treatment Directive will have on European patients...
Read Article -
Statements & press releases 16.10.24
Coalition of 43 Business Associations Rallies Behind Call for Bold & Open Trade Policy to Keep Europe...
As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold...
Read Article -
Statements & press releases 17.09.24
EFPIA responds to the announcement of the College of Commissioners and publication of their mission letters...
EFPIA, Vaccines Europe and our members congratulate all the Commissioner-designates on their proposed roles.
Read Article -
Statements & press releases 09.09.24
EFPIA response to Mario Draghi EU competitiveness report
EFPIA welcomes recognition of the innovative pharmaceutical sector’s importance to EU competitiveness and calls for swift adoption of the recommendations....
Read Article
No results found for “”
No results found for filter “”
-
Blog articles 11.12.24
The origins and privileges of self-regulation
Self-regulation plays a vital role in governing how pharmaceutical companies promote medicines, interact with health professionals and collaborate with...
Read Article -
Blog articles 09.12.24
EFPIA response to ‘Guidance on outcomes for joint clinical assessments’
We remain optimistic that the flexibility included in the guideline is applied by the assessors in a pragmatic approach. Looking into the future, we hope...
Read Article -
Blog articles 04.12.24
Resetting Europe’s Innovation Compass
Europe’s pharmaceutical sector has grown slowly for 25 years and its share of research is shrinking. It’s time to turn things around.
Read Article -
Blog articles 20.11.24
European Antibiotic Awareness Day: Urgent Need for Sustainable Antimicrobial R&D to Combat Superbugs
In Europe alone, antimicrobial resistance or AMR results in 35,000 deaths annually, with healthcare costs and productivity losses estimated at €1.5 billion...
Read Article -
Blog articles 14.11.24
INNODIA: A Success Story in Type 1 Diabetes Research and Treatment (Guest blog)
Type 1 Diabetes (T1D) is an autoimmune disease where the body’s own immune system mistakenly attacks insulin-producing beta cells in the pancreas. It’s...
Read Article -
Blog articles 13.11.24
Filling the Gaps in Care: Driving Change through Embracing Carers® (Guest blog)
Supporting informal carers isn’t just about helping; it’s about elevating entire communities.
Read Article -
Blog articles 10.11.24
Navigating Certainty and Analytical Complexity: Industry’s Reflections on Ensuring Scientific Rigor and...
The HTA Regulation (HTAR) requires that Joint Clinical Assessments (JCAs) describe the certainty of a health technology’s effects by considering the strengths...
Read Article -
Blog articles 29.10.24
Around the world of evidence synthesis (in eighty pages): the methodological and practical guidelines...
Application of the European HTA Regulation is around the corner - in only a few months from now, the first products will go through the new European Joint...
Read Article -
Blog articles 28.10.24
Chasing bold goals to unlock new solutions
Learn more about Timothy Radstake, Vice President and Global Head of Immunology Discovery Research at AbbVie, and his efforts to drive innovation, close...
Read Article -
Blog articles 24.10.24
Let’s dig deeper on Unmet Medical Need (Guest Blog)
Stefan Frings explains why a broad, encompassing definition of Unmet Medical Need, is key in R&D investment decisions.
Read Article -
Blog articles 23.10.24
Overcoming the barriers to Europe’s leadership in medical innovation
Over the years, Europe’s share of global medicine R&D investments has dropped. However, with the new EU mandate, there is a chance to turn this around......
Read Article -
Blog articles 15.10.24
Advancing the precision oncology agenda in the EU: developing a roadmap at country level to address the...
Access to precision oncology is essential to ensure optimal and timely treatment of patients with cancer. However, challenges to access precision oncology...
Read Article